CLACENDIX, INC. Form 10-Q May 20, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

OF 1934

For the quarterly period ended March 31, 2008

OR

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

OF 1934

For the transition period from ______ to _____

Commission File Number: 0-13117

Clacendix, Inc.

Exact Name	e of registrant	as specified	in Its	Charter
LACCI Talli	c of regionalit	as specifica	111 111	5 Charter

Delaware	22-2413505
(State or Other Jurisdiction of	(IRS Employer Identification Number)
Incorporation or Organization)	
	201Route 46 Parsippany, NJ 07054
(Addres	ss of Principal Executive Offices) (Zip Code)
	<u>(973) 402-4251</u>
	(Registrant s telephone number)
Securities Exchange Act of 1934 during	estrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the g the proceeding 12 months (or for such shorter period that the registrant was s been subject to such filing requirements for the past 90 days: Yes X No
Indicate by check mark whether the region a smaller reporting company. See the company in Rule 12b-2 of the Exchange	
Large accelerated filer	
Accelerated filer	

Non-accelerated filer (Do not check if a smaller reporting company)
Smaller reporting Company X
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes X No
There were 33,047,161 shares of Common Stock outstanding as of May 19, 2008.

Edgar Filing: CLACENDIX, INC. - Form 10-Q CLACENDIX, INC. AND SUBSIDIARY

FORM 10-Q

FOR THE QUARTER ENDED March 31, 2008

PART I. FINANCIAL INFORMATION

Page
Item 1. Financial Statements
3
Condensed Consolidated Balance Sheet as of March 31, 2008 (Unaudited) and December 31, 2007 4
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2008 and 2007(Unaudited) 5
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2008 and 2007 (Unaudited)

Notes to Condensed Consolidated Financial Statements (Unaudited)
7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
10
Item 3. Quantitative and Qualitative Disclosure about Market Risk
13
Item 4. Controls and Procedures
13
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
14
Item 6. Exhibits
15
SIGNATURES
16

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The condensed consolidated financial statements included herein have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. It is suggested that these financial statements be read in conjunction with the audited financial statements and the notes thereto included in our report on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

CLACENDIX, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEET

Assets

	M	arch 31, 2008 (Unaudited)		December 31,
				2007
Current assets		r.		
Cash and cash equivalents		\$ 1,904,271	\$	2,525,641
Restricted cash		321,460	Ψ	320,000
Other receivables		42,205		397,868
Prepaid expenses and other current assets		9,419		9,527
Total assets		\$,
		2,277,355	\$	3,253,036
Liabilities and Stockholders Equity				
Current liabilities				
Accounts payable	\$	177,223	\$	333,880
Accrued expenses	·	111,740	·	164,248
Accrued payroll and related liabilities		343,512		897,248
Accrued interest related party		15,814		15,814
Total liabilities		648,289		1,411,190
Commitments and contingencies				
Stockholders Equity				
Preferred stock par value \$.001 per share; authorized 1,000,000 shares;				
200,000 shares designated Series A; 155,557 shares issued and				
outstanding (aggregate liquidation preference \$280,003)		156		156
Common stock par value \$.001 per share; authorized 50,000,000				
shares;		33,048		33,048
33,047,161 shares issued and outstanding		,-		,
Additional paid-in capital		45,864,458		45,862,529
Accumulated deficit		(44,268,596)		(44,053,887)

Total stockholders equity		1,629,066	1,841,846
Total liabilities and stockholders	equity	\$ 2,277,355	\$ 3,253,036

The accompanying notes are an integral part of these condensed consolidated financial statements.

CLACENDIX, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

		or the Three onths Ended		the Three ths Ended
	Ma	arch 31, 2008	Marc	h 31, 2007
Net sales		\$ -	\$	942,962
Cost of sales		-		410,335
Gross margin		-		532,627
Operating expenses:				
Research and development		236		84,922
Selling, general and administrative expenses		230,117		656,806
Depreciation expense		-		5,093
Total operating expenses		230,353		746,821
Loss from operations		(230,353)		(214,194)
Interest income(expense)		15,644		(16,009)
Loss before income taxes		(214,709)		(230,203)
Income tax expense		-		3,052
Net loss	\$	(214,709)		\$ (233,255)

Per share data:

Net loss per common share

Basic and diluted \$ (0.01) \$ (0.01)

Weighted average number of common

shares outstanding

Basic and diluted 33,047,161 32,785,565

The accompanying notes are an integral part of these condensed consolidated financial statements.

CLACENDIX, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the Three Months		For the Three Months	
Ended March 31, 2008		End	led March 31, 2007
\$	(214,709)	\$	(233,255)
-		87,98	80
1,92	29	58,981	
-		22,643	
-		(7,603)	
-		824	
-		9,041	
(1,460)		-	
- (99,851)		351)	
355,663 -			
-		181,0	001
108		(42,8	354)
-		10,08	85
(150	6,657)	(38,360)	
(52,508)		1,726	
(553	3,736)	(10,4	198)
-		59,86	57
(621,370) (273))	
	Err \$ - 1,92 (1,4 - 355 - 108 - (156 (52,655)	Months Ended March 31, 2008 \$ (214,709) - 1,929 (1,460) - 355,663 - 108 - (156,657) (52,508) (553,736) -	Months Ended March 31, 2008 \$ (214,709) \$ - 87,98 1,929 58,98 - 22,66 - (7,60 - 824 - (9,04) (1,460) - - (99,8) 355,663 181,6 108 (42,8) - (156,657) (38,3) (156,657) (38,3) (52,508) 1,726 (553,736) (10,4) - 59,86

Cash flows from investing activities

Edgar Filing: CLACENDIX, INC. - Form 10-Q

Capitalized software expenditures				(180,776)		
Net cash used in investing a	activities	-		(180,77	6)	
Cash flows from financing	activities					
Principal payments on debt and capital leases				(624)		
Repayment of revolving credit facility				(31,139)	(31,139)	
Net cash provided by financing activities		-		(31,763))	
Net decrease in cash and cash equivalents		(621,	370)	(212,81	2)	
Cash and cash equivalents	beginning of period	2,525	,641	265,936		
Cash and cash equivalents	end of period	\$	1,904,271	\$	53,124	

The accompanying notes are an integral part of these condensed consolidated financial statements.

CLACENDIX, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2008

(Unaudited)

NOTE 1 ORGANIZATION, BASIS OF PRESENTATION AND PLAN OF OPERATION

Organization and Basis of Presentation

Clacendix, Inc., a Delaware corporation was founded, as ION Networks, Inc. (ION), in 1999 through the combination of two companies -- MicroFrame, a New Jersey Corporation, and SolCom Systems Limited, a Scottish corporation located in Livingston, Scotland. ION designed, developed, manufactured and sold network and information security and management products to corporations, service providers and government agencies. On December 31, 2007, ION Networks, Inc. changed its name to Clacendix, Inc., in connection with the sale of substantially all of its operating assets to Cryptek, Inc., a Delaware Corporation (Cryptek), as described below. The accompanying condensed consolidated financial statements include the accounts of Clacendix, Inc. and ION Networks, N.V., a wholly-owned, inactive subsidiary (collectively, the Company). All material inter-company balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of March 31, 2008, and the condensed consolidated statements of operations and cash flows for the three months ended March 31, 2008 and 2007, have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to make the Company's financial position, results of operations and cash flows at March 31, 2008 and for the three months ended March 31, 2008 and 2007 not misleading have been made. The results of operations for the three months ended March 31, 2008, are not necessarily indicative of results that would be expected for the full year or any other interim period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the audited financial statements and notes thereto included in the report on Form 10-KSB for the year ended December 31, 2007, filed with the Securities and Exchange Commission.

On December 31, 2007, the Company sold substantially all of the operating assets of the Company to Cryptek, Inc. Stockholder approval was required, and obtained, with respect to such sale. Since the date of this transaction, the Company existed as a shell company with no operations.

Plan of Operation

The plan of operation of the Company is to seek a target company with which to merge or to complete a business combination. In any transaction, it is expected that the Company would be the surviving legal entity and the shareholders of the Company would retain a percentage ownership interest in the post-transaction company. The Company does not plan to restrict its search to any specific business, industry or geographic location, and it may participate in a business venture of virtually any kind or nature.

The Company may seek a business opportunity with entities which have recently commenced operations, or that desire to utilize the public marketplace in order to raise additional capital in order to expand into new products or markets, to develop a new product or service, or for other corporate purposes. The Company may acquire assets and establish wholly owned subsidiaries in various businesses or acquire existing businesses as subsidiaries.

The Company can give no assurance that any such a transaction will occur, or that if such a transaction were to occur, it would enhance the Company s future operations or financial results, or specifically that the Company would become and remain profitable as a result of such transaction. If the Company is not able to complete a transaction within a reasonable time frame, the Company may liquidate.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Net Loss Per Share of Common Stock

Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. Potentially dilutive securities of 5,964,061 and 10,326,608 at March 31, 2008 and 2007, respectively are excluded from the computation of diluted net loss per share, as their inclusion would be antidilutive.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with the fair value recognition provisions of Statement of Financial Accounting Standards No. 123R, entitled Share Based Payment (FAS 123R). Stock-based compensation expense for all share-based payment awards is based on the grant-date fair value estimated in accordance with the provisions of FAS 123R. The Company recognizes these compensation costs over the requisite service period of the award, which is generally the option vesting term. As of March 31, 2008, the fair value of unvested options totaled \$5,975. Stock based compensation for the three months ended March 31, 2008 and 2007 was recorded in the accompanying condensed consolidated statements of operations as follows:

	For the three months ended March 31,			
	2008	2007		
Cost of Sales	\$ -	\$ 1,831		
Research & Development	-	17,485		
Selling General &Administrative	1,929	39,665		
Totals	\$ 1,929	\$58,981		

The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model with the following assumptions and weighted average fair values as follows:

	Three months ended
	March 31, 2008
Risk-free interest rate	2.61%
Dividend yield	N/A
Expected volatility	227%
Expected life in years	5
Expected forfeiture rate (through term)	0%

The Company accounts for the expected life of share options in accordance with the simplified method provisions of Securities and Exchange Commission Staff Accounting Bulletin (SAB) No. 110 (December 2007), which enables the use of the simplified method for plain vanilla share options as defined in SAB No. 107.

A summary of option activity for the three months ended March 31, 2008 is as follows:

Weighted-

Edgar Filing: CLACENDIX, INC. - Form 10-Q


Weighted-Average Average Remaining Aggregate Exercise Contractual Intrinsic Term Options Shares Price Value Outstanding at January 1, 5,490,407 \$0.27 2.75 years 2008 Granted 4,500 \$0.03 5.00 years Canceled (2,625,003)\$0.42 3.43 years Outstanding at March 31, 2,869,904 1.38 years \$0.13 \$-2008 Exercisable at March 31, 2008 2,704,904 1.29 years \$-\$0.13

The weighted-average grant-date fair value of options granted during the three months ended March 31, 2008 amounted to \$0.03 per share.

NOTE 3 STOCKHOLDERS EQUITY

Common Stock

On December 31, 2007, at the Company s annual shareholders meeting, the shareholders approved a proposal to amend Article Fourth of the certificate of incorporation of the Company to increase the number of authorized shares of common stock from



NOTE 4 CONTINGENT LIABILITIES

In the normal course of business the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Management is not aware of any item existing that will have a significant impact on the Company s business or financial condition.

NOTE 5 NEW ACCOUNTING PRONOUNCEMENTS

price of \$0.03 for a total value of \$135, based on the Black-Scholes model.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities-an amendment of FASB Statement No. 133 (SFAS 161), to require enhanced disclosures about an entity s derivative and hedging activities and thereby improves the transparency of financial reporting. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early adoption encouraged. The Company is currently evaluating the effect that the adoption of SFAS 161 will have on its consolidated results of operations and financial condition, but does not expect it to have a material impact.

In February 2008, the FASB issued Staff Position No. 157-2, Effective Date of FASB Statement No. 157 (FSP 157-2) that defers the effective date of applying the provisions of SFAS 157 to the fair value measurement of non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (or at least annually), until fiscal years beginning after November 15, 2008. The Company is currently evaluating the effect that the adoption of FSP 157-2 will have on its consolidated results of operations and financial condition, but does not expect it to have a material impact.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS 159) including an amendment of FASB Statement No. 115. SFAS 159 permits companies to choose to measure certain financial instruments and certain other items at fair value. The standard requires that unrealized gains and losses on items for which the fair value option has been elected be reported in earnings. The Company adopted SFAS 159 beginning in the first quarter of 2008, without material effect on the Company s consolidated financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157 provides guidance for using fair value to measure assets and liabilities. It also responds to investors requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value, and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007 and has been adopted by the Company in 2008 without material effect on the Company s consolidated financial position or results of operations.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Information Regarding Forward-Looking Statements

A number of statements contained in this report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. You can identify forward-looking statements by our use of words such as may , will , should , could , expects , plans , intends , anticipates , believes , potential , or continue or the negative or other variations of these words, or other comparable words or phrases. These statements include, but are not limited to, statements regarding our ability to complete our business objectives. These risks and uncertainties include, but are not limited to:

our ability to complete a combination with one or more target businesses;
our success in retaining or recruiting, or changes required in, our officers or directors following a business combination;
our potential inability to obtain additional financing to complete a business combination;
a limited pool of prospective target businesses;
a potential change in control if we acquire one or more target businesses for stock;
our public securities limited liquidity and trading; or
our ongoing financial performance.
Unless otherwise required by applicable law, the Company assumes no obligation to update any such forward-l

Unless otherwise required by applicable law, the Company assumes no obligation to update any such forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. These risk factors are further described in our annual report on Form 10-KSB for the fiscal year ended December 31, 2007.

OVERVIEW

Clacendix, Inc., a Delaware corporation was founded, as ION Networks, Inc. (ION), in 1999 through the combination of two companies -- MicroFrame, a New Jersey Corporation, and SolCom Systems Limited, a Scottish corporation located in Livingston, Scotland. ION designed, developed, manufactured and sold network and information security and management products to corporations, service providers and government agencies. On December 31, 2007, ION Networks, Inc. changed its name to Clacendix, Inc. The accompanying condensed consolidated financial statements include the accounts of Clacendix, Inc. and ION Networks, N.V., a wholly-owned, inactive subsidiary (collectively, the Company).

This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report. This discussion includes forward-looking statements that involve risk and uncertainties. The following financial information for the year ended December 31, 2007, and the periods ended March 31, 2008 and March 31, 2007 should be considered in light of the completion of the sale of substantially all of the operating assets of the Company on December 31, 2007 and the fact that the Company currently has no operations other than to seek a target company with which to merge or to complete a business combination, as further described in our Annual Report on Form 10-KSB for the year ended December 31, 2007. The Company can give no assurance that any such a transaction will occur, or that if such a transaction were to occur, it would enhance the Company s future operations or financial results, or specifically that the Company would become and remain profitable as a result of such transaction. The Company will not generate any future revenues until, at the earliest, after the consummation of a business combination. If the Company is not able to complete a transaction within a reasonable time frame, the Company may liquidate.

On December 31, 2007, the Company sold substantially all of its operating assets to Cryptek, Inc., a privately held Delaware Corporation. Stockholder approval was required, and obtained, with respect to such sale.

RESULTS OF OPERATIONS

For the three months ended March 31, 2008 compared to the same period in 2007:

Net sales for the three months ended March 31, 2008, were zero compared to net sales of \$942,962 for the same period in 2007. The decrease in revenue for first quarter of 2008 compared to the same period last year was due to the sale of substantially all the operating assets of the Company on December 31, 2007.

Cost of sales for the three months ended March 31, 2008 was zero compared to \$410,335 for the same period in 2007. The decrease in cost of sales for first quarter of 2008 compared to the same period last year was due to the sale of substantially all the operating assets of the Company on December 31, 2007.

Research and development expenses for the three months ended March 31, 2008 was \$236 compared to \$84,922 for the same period in 2007 or a decrease of \$84,686. The decrease in research and development expenses for first quarter of 2008 compared to the same

period last year was due to the sale of substantially all the operating assets of the Company on December 31, 2007.

Selling, general and administrative expenses ("SG&A") for the three month ended March 31, 2008 were \$230,117 compared to \$656,806 for the same period in 2007, a decrease of \$426,689. The decrease in SG&A expenses was due to the sale of substantially all the operating assets of the Company on December 31, 2007. SG&A expenses for the three months ended March 31, 2008 comprised mainly of payroll related expenses for salaries, benefits and incentive compensation of \$160,971 and professional fees of \$46,633.

Depreciation expense was zero for the three months ended March 31, 2008 compared to \$5,093 in the same period in 2007. The decrease in depreciation expense for first quarter of 2008 compared to the same period last year was due primarily to the sale of substantially all the operating assets of the Company on December 31, 2007.

The Company incurred a net loss of \$214,709 for the three months ended March 31, 2008, compared to \$233,255 for the same period in 2007. The decrease was due lower general overhead resulting from the sale of substantially all the operating assets of the Company on December 31, 2007. Net loss for the three months ended March 31, 2008 includes approximately \$30,000 of non-recurring expenses due to payroll related expenses was related to severance payments made to former employees.

FINANCIAL CONDITION AND CAPITAL RESOURCES

The Company's working capital balance as of March 31, 2008 was \$1,629,066 as compared to \$1,841,846 at December 31, 2007. The decrease of \$212,780 was due to factors noted above, principally lower operating expenses due to the sale of substantially all the operating assets of the Company. We presently anticipate that cash requirements during the next twelve months will relate to maintaining the corporate entity, complying with the periodic reporting requirements of the Securities and Exchange Commission, evaluating and reviewing possible business ventures and acquisition opportunities and potentially negotiating and consummating any such transactions. The Company believes that it has sufficient cash on hand to meet these cash requirements during the next year.

Net cash used in operating activities during the three months ended March 31, 2008 was \$619,910 compared to \$273 in the same period in 2007, a difference of \$619,637. The use of cash in the three months ended March 31, 2008 included severance of \$508,736 and deferred payroll of \$52,000.

Net cash used in investing activities during the three months ended March 31, 2008 was zero compared to net cash used during the same period in 2007 of \$180,776. Capitalized software expenditures for the three months ended March 31, 2007 were \$180,776 and zero for the three months ended March 31, 2008.

Net cash used by financing activities during the three months ended March 31, 2008 was zero compared to net cash provided by financing activities during the three months ended March 31, 2007 of \$31,763. In the first quarter of 2007, the Company made repayments on the credit facility of \$31,139.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with the fair value recognition provisions of Statement of Financial Accounting Standards No. 123R, entitled Share Based Payment (FAS 123R). Stock-based compensation expense for all share-based payment awards is based on the grant-date fair value estimated in accordance with the provisions of FAS 123R. The Company recognizes these compensation costs over the requisite service period of the award, which is generally the option vesting term. As of March 31, 2008, the fair value of unvested options totaled \$5,975. Stock based compensation for the three months ended March 31, 2008 was \$1,929.

The Company accounts for the expected life of share options in accordance with the simplified method provisions of Securities and Exchange Commission Staff Accounting Bulletin (SAB) No. 110 (December 2007), which enables the use of the simplified method for plain vanilla share options as defined in SAB No. 107.

Recent Accounting Pronouncements

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities-an amendment of FASB Statement No. 133 (SFAS 161), to require enhanced disclosures about an entity s derivative and hedging activities and thereby improves the transparency of financial reporting. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early adoption encouraged. The Company is currently evaluating the effect

that the adoption of SFAS 161 will have on its consolidated results of operations and financial condition, but does not expect it to have a material impact.

In February 2008, the FASB issued Staff Position No. 157-2, Effective Date of FASB Statement No. 157 (FSP 157-2) that defers the effective date of applying the provisions of SFAS 157 to the fair value measurement of non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (or at least annually), until fiscal years beginning after November 15, 2008. The Company is currently evaluating the effect that the adoption of FSP 157-2 will have on its consolidated results of operations and financial condition, but does not expect it to have a material impact.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (SFAS 159) including an amendment of FASB Statement No. 115. SFAS 159 permits companies to choose to measure certain financial instruments and certain other items at fair value. The standard requires that unrealized gains and losses on items for which the fair value option has been elected be reported in earnings. The Company adopted SFAS 159 beginning in the first quarter of 2008, without material effect on the Company s consolidated financial position or results of operations.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157 provides guidance for using fair value to measure assets and liabilities. It also responds to investors requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value, and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007 and has been adopted by the Company in 2008 without material effect on the Company s consolidated financial position or results of operations.

Off-Balance Sheet Arrangements

As of May 19, 2008, we did not have any off-balance sheet debt nor did we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that may have a material current or future effect on financial conditions, changes in financial conditions, result of operations, liquidity, capital expenditures, capital resources, or significant components of revenue or expenses.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not App	licable.
---------	----------

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Prior to the filing of this report, the Company s management carried out an evaluation, under the supervision and with the participation of its Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company s disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company's controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed by the Company in the reports filed by it under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.

Changes to Internal Control Over Financial Reporting

There are no changes in the Company s internal control over financial reporting during the three months ended March 31, 2008 that have materially affected, or are reasonably likely to materially affect, the Company s internal control over financial reporting. However, as the Company sold substantially all of its operating assets on December 31, 2007 it has continued to utilize the accounting system, which was sold in the transaction, as well as certain Cryptek employees through mutual agreement for a period of time. During the fiscal year 2008, the Company will evaluate continuing this relationship.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not currently involved in any legal proceedings other than routine litigation incidental to the business.

ITEM 6. EXHIBITS

31.1	*	Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)
31.2	*	Certification of Chief Financial Officer pursuant to Securities Exchange
		Act Rule 13a-14(a)
32.1	*	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

- * Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, of Chief Executive Officer
- * Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, of Chief Financial Officer

^{*} Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 20, 2008

CLACENDIX, INC.

/S/ Norman E. Corn

Norman E. Corn, Chief Executive Officer

/S/ Patrick I	E. Delaney	

Patrick E. Delaney, Chief Financial Officer

Exhibit Index

- 31.1 * Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)
- 31.2 * Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)
- 32.1 * Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, of Chief Executive Officer
- 32.2 * Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, of Chief Financial Officer

* Filed herewith